US rare diseases focused biopharma company Catalyst Pharmaceuticals (Nasdaq: CPRX) today announced that the company is reducing its workforce by approximately 30%.
The reduction in workforce, which affects employees from Catalyst’s commercial team, is part of the company’s ongoing efforts to conserve cash as it works to complete the requirements for a New Drug Application submission of Firdapse (amifampridine phosphate) for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS).
Catalyst licensed North American rights to Firdapse in 2012, from fellow US firm BioMarin (Nasdaq: BMRN), which launched the drug in Europe six years ago (The Pharma Letter April 20, 2010).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze